Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

111 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-23

Study Completion Date

2018-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Primary objective of this study is to compare serum levels of Macrophage-Colony Stimulating Factor (M-CSF) in a population of patients with multiple myeloma (MM), in a population of patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and in a control population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunophenotyping of Plasma Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From Multiple Myeloma (MM) Patients

NCT05428163

Multiple Myeloma

COMPLETED

Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma

NCT02302495

Multiple Myeloma

COMPLETED PHASE2

S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

NCT00900263

Multiple Myeloma Plasma Cell Myeloma Precancerous Condition

COMPLETED

MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis?

NCT03618212

Myeloma

TERMINATED

Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care

NCT04111809

Multiple Myeloma

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

multiple myeloma group

case group = patients with multiple myeloma

Group Type EXPERIMENTAL

blood samples

Intervention Type BIOLOGICAL

Bone marow samples

Intervention Type BIOLOGICAL

MGUS group

monoclonal gammopathy of undetermined significance

Group Type EXPERIMENTAL

blood samples

Intervention Type BIOLOGICAL

Bone marow samples

Intervention Type BIOLOGICAL

healthy control group

control group = healthy subjects

Group Type OTHER

blood samples

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood samples

Intervention Type BIOLOGICAL

Bone marow samples

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For the multiple myeloma group

* confirmed diagnosis of de novo multiple myeloma according to the International Myeloma Working Group criteria
* bisphosphonate therapy for more than 60 days,
* signature of the informed consent form,
* patients over the age of 18 years. For the monoclonal gammopathy of undetermined significance (MGUS) group
* confirmed diagnosis of MGUS according to the International Myeloma Working Group criteria
* signature of the informed consent form,
* patients over the age of 18 years. For the healthy control group
* signature of the informed consent form,
* subjects over the age of 18 years.

Exclusion Criteria

* patients with thyroid or parathyroid disease,
* osteomalacia, rheumatoid arthritis, Paget's disease, osteoporosis,
* bisphosphonate therapy for less than 60 days,
* absence of informed consent,
* patients under the age of 18 years.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes